ctDNA Clinical Trials

9 recruiting

ctDNA Trials at a Glance

11 actively recruiting trials for ctdna are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Shanghai, Shanghai, and Montpellier. Lead sponsors running ctdna studies include Fudan University, Erasmus Medical Center, and Samsung Medical Center.

Browse ctdna trials by phase

Treatments under study

About ctDNA Clinical Trials

Looking for clinical trials for ctDNA? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ctDNA trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ctDNA clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer

ChemotherapyctDNA
Fudan University100 enrolled1 locationNCT07562490
Recruiting
Phase 2

Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer

ctDNA
Fudan University340 enrolled1 locationNCT07562503
Recruiting
Phase 2

Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer

ctDNAColorectal Cancer (CRC)Adjuvant Chemotherapy
Fudan University80 enrolled1 locationNCT07562659
Recruiting
Phase 2

Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer

ChemotherapyctDNA
Fudan University340 enrolled1 locationNCT07562711
Recruiting
Not Applicable

A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring

Esophageal CancerctDNA
The Central Hospital of Lishui City30 enrolled2 locationsNCT06792786
Recruiting
Phase 2

ctDNA-guided Treatment Decision-making

Metastatic Breast Cancer ( HER2 Negative)ctDNA
Fudan University122 enrolled1 locationNCT07394218
Recruiting

Feasibility of Circulating Tumour DNA (ctDNA) Analysis Using Automated Capillary Blood Sampling

Colorectal Cancer (Diagnosis)Colorectal Liver Metastasis (CRLM)Circulating Tumor DNA (ctDNA)
Erasmus Medical Center35 enrolled1 locationNCT07310537
Recruiting

Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)

Metastatic Colorectal Cancer ctDNA Surveillance
Fudan University497 enrolled1 locationNCT07283575
Recruiting

A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening

ctDNAGall Bladder CancerIntrahepatic Cholangiocarcinoma (Icc)+3 more
Yingbin Liu, MD, PhD, FACS1,800 enrolled1 locationNCT07176962
Recruiting

SMC Radiation Oncology SABR Cohort for Oligometastasis

OligometastasisctDNAPatient-Reported Outcomes (PRO)+2 more
Samsung Medical Center60 enrolled1 locationNCT07121335
Recruiting

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Pancreatic Ductal AdenocarcinomaMinimal Residual DiseasectDNA+2 more
University Hospital, Montpellier37 enrolled1 locationNCT06287749